Minerva Surgical, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Minerva Surgical, Inc. - overview
Established
2008
Location
Santa Clara, CA, US
Primary Industry
Medical Devices & Equipment
About
Based in California, US, and founded in 2008 by founders David M. Clapper (CEO) and Csaba Truckai, Minerva Surgical, Inc. operates as a medical device developer that treats abnormal uterine bleeding. The first product from the firm, the Minerva ES, was released in 2015.
In December 2016, the company raised USD 16. 72 million in funding. In 2020, Minerva Surgical acquired three additional devices for the treatment of AUB, such as Symphion, Genesys HTA, and Resectr. As of October 2021, Minerva Surgical shares began trading on the Nasdaq Global Market under the ticker symbol "UTRS.
Minerva Surgical, Inc. 's devices such as Minerva ES, Symphion, Genesys HTA, and Resectr support the endometrial lining of the uterus in premenopausal women who have menorrhagia due to various causes and have finished childbearing, allowing healthcare providers to give women, ideas to take efficient management of their menstrual cycle. The company generates its revenue by marketing and selling its products through a direct sales force in the US. Minerva Surgical earned USD 52 million in revenue for the fiscal year ending June 2021.
Current Investors
Versant Ventures, New Enterprise Associates, Novo Holdings
Primary Industry
Medical Devices & Equipment
Sub Industries
Healthcare, Therapeutic Devices, Surgical Devices
Website
www.minervasurgical.com
Verticals
HealthTech, Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Minerva Surgical, Inc. - timeline of key events
Minerva Surgical, Inc. - financials
| Fiscal Year Ended | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
|---|---|---|---|---|
| Revenue (USD) | 26,000,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - |
| EBITDA (USD) | (13,700,000) | - | - | - |
| Operating Income (USD) | (19,600,000) | - | - | - |
| Operating Margin | (75.4%) | - | - | - |
| % EBITDA Margin | (52.7%) | - | - | - |
| NET Income (USD) | (52,000,000) | - | - | - |
| % Net Margin | (200.0%) | - | - | - |
Minerva Surgical, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.